Compare SSD & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSD | KYMR |
|---|---|---|
| Founded | 1956 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.8B |
| IPO Year | 1996 | 2020 |
| Metric | SSD | KYMR |
|---|---|---|
| Price | $173.73 | $74.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 26 |
| Target Price | ★ $206.00 | $107.72 |
| AVG Volume (30 Days) | 193.0K | ★ 615.0K |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | ★ 8.42 | N/A |
| EPS | ★ 8.24 | N/A |
| Revenue | ★ $2,332,808,000.00 | $39,211,000.00 |
| Revenue This Year | $3.82 | $11.85 |
| Revenue Next Year | $5.57 | $7.79 |
| P/E Ratio | $20.95 | ★ N/A |
| Revenue Growth | ★ 4.51 | N/A |
| 52 Week Low | $137.35 | $19.45 |
| 52 Week High | $211.98 | $103.00 |
| Indicator | SSD | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 34.95 | 35.15 |
| Support Level | $163.95 | $64.95 |
| Resistance Level | $187.60 | $77.93 |
| Average True Range (ATR) | 4.49 | 3.66 |
| MACD | -1.52 | -1.19 |
| Stochastic Oscillator | 27.57 | 5.84 |
Simpson Manufacturing Co Inc designs, manufactures, and markets systems and products to make buildings and structures safe and secure. It produces wood construction products, including connectors, truss plates, fastening systems, fasteners, and shearwalls, as well as concrete construction products such as adhesives, specialty chemicals, mechanical anchors, powder actuated tools, and fiber reinforcing materials. The company serves residential, industrial, commercial, and infrastructure construction, remodeling, and do-it-yourself markets, operating exclusively in the building products industry. It has three regional segments: North America, Europe, and Asia/Pacific. The majority of its revenue comes from wood products.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.